The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is
"The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
The subject is able and willing to provide and sign informed consent
The subject must be between 18 and 80 years of age
The subject should have chronic kidney disease as defined by glomerular filtration rate
The surgery must require general anesthesia with endotracheal intubation and neuromuscular blockade
Any patient under the age of 18
Any patient over the age of 80
Any patient with end stage renal disease
Any patient requiring dialysis